Abstract:Huiling Ma, 1, 2 Xinyu Zhao, 1 Longbing Yang, 1 Peipei Su, 1 Ping Fu, 1, 3 Jian Peng, 1, 3 Na Yang, 4 Guo Guo 1, 3, 4 1 Key and Characteristic Laboratory of Modern Pathogen Biology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550025, People's Republic of China; 2 Department of Pathogen Biology and Immunology, School of Basic Medical Sciences, Sanquan College of Xinxiang Medical University, Xinxiang 453003, People's Republic of China; 3 Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang 550025, People's Republic of China; 4 School of Food Science, Guizhou Medical University, Guiyang 550025, People's Republic of China Correspondence: Guo Guo Tel +86 13765024379 Email guoguojsc@163.com Background: Candida albicans is associated with high mortality among immunocompromised patients. Resistance to and toxic side effects of antifungal drugs require the development of alternative antifungal agents. AMP-17 is a novel antimicrobial peptide derived from Musca domestica that exerts excellent antifungal effects against the Candida species. In this article, we discuss the potential mechanism of AMP-17 against C. albicans from the perspective of affecting the latter's cell external structure. Methods: Recombinant AMP-17 was prepared by prokaryotic expression system, and its anti- C. albicans activity was detected by microdilution method. Microscopy and scanning electron microscopy were used to examine morphological changes in C. albicans . Cell wall-specific staining method was used to detect the change of cell wall integrity of C. albicans after AMP-17 treatment. AMP-17-induced damage to the C. albicans cell membrane was analyzed by fluorescent probes and glycerol assay kit. The expression of genes related to fungal cell wall and cell-membrane synthesis was detected by qRT-PCR. Results: Morphological observations showed that the growth of C. albicans was significantly inhibited in AMP-17-treated cells; the cells appeared aggregated and dissolved, with severe irregularities in shape. Furthermore, AMP-17 damaged the integrity of C. albicans cell walls. The cell wall integrity rate of AMP-17-treated cells was only 21.7% compared to untreated cells. Moreover, the change of membrane dynamics and permeability suggested that the cell membrane was disrupted by AMP-17 treatment. Genetic analysis showed that after AMP-17 treatment, the cell wall synthesis-related gene FKS2 of C. albicans was up-regulated 3.46-fold, while the cell membrane ergosterol synthesis-related genes ERG1, ERG5, ERG6 , and MET6 were down-regulated 5.88-, 17.54-, 13.33-, and 7.14-fold, respectively. Conclusion: AMP-17 treatment disrupted the cell wall integrity and membrane structure of C. albicans and is likely a novel therapeutic option for prevention and control of C. albicans infections. Keywords: AMP-17, C. albicans , cell wall, membrane dynamics and permeability

Inhibition of Candida albicans in vivo and in vitro by antimicrobial peptides chromogranin A-N12 through microRNA-155/suppressor of cytokine signaling 1 axis

Protective Effect of a Novel Antifungal Peptide Derived from Human Chromogranin a on the Immunity of Mice Infected with Candida Krusei.

Transcriptional Responses of Candida albicans to Antimicrobial Peptide MAF-1A

Antimicrobial peptide AMP-17 induces protection against systemic candidiasis and interacts synergistically with fluconazole against Candida albicans biofilm

Antimicrobial Peptide CGA-N12 Decreases the Candida Tropicalis Mitochondrial Membrane Potential Via Mitochondrial Permeability Transition Pore

A Cecropin-4 Derived Peptide C18 Inhibits Candida albicans by Disturbing Mitochondrial Function

Antifungal activity of MAF-1A peptide against Candida albicans

ASLdC3: A Derivative of Acidic Sophorolipid Disrupts Mitochondrial Function, Induces ROS Generation, and Inhibits Biofilm Formation in Candida albicans

Preventing Candida Albicans from Subverting Host Plasminogen for Invasive Infection Treatment.

Rational design, synthesis, antifungal evaluation and docking studies of antifungal peptide CGA-N12 analogues based on the target CtKRE9

Internalization and membrane activity of the antimicrobial peptide CGA-N12

A Novel Antimicrobial Peptide Derived from Human BPIFA1 Protein Protects Against Candida Albicans Infection.

Activity and mechanism of action of antimicrobial peptide ACPs against Candida albicans

The Antimicrobial Peptide AMP-17 Derived from Musca domestica Inhibits Biofilm Formation and Eradicates Mature Biofilm in Candida albicans

Sodium New Houttuyfonate Inhibits Candida albicans Biofilm Formation by Inhibiting the Ras1-cAMP-Efg1 Pathway Revealed by RNA-seq

Exploring the Therapeutic Potential of Scorpion-Derived Css54 Peptide Against Candida albicans

Characterization of the transcriptional response of Candida parapsilosis to the antifungal peptide MAF-1A

Antimicrobial Peptide AMP-17 Affects Candida albicans by Disrupting Its Cell Wall and Cell Membrane Integrity

Candida tropicalis oligopeptide transporters assist in the transmembrane transport of the antimicrobial peptide CGA-N9

Symbiotic NCR Peptide Fragments Affect the Viability, Morphology and Biofilm Formation of Candida Species

β-1,3-Glucan/CR3/SYK pathway-dependent LC3B-II accumulation enhanced the fungicidal activity in human neutrophils